News about "metastatic breast cancer "

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer

Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.

Metastatic Breast Cancer | 19/03/2026 | By News Bureau

Medicines and Healthcare products Regulatory Agency Approves Inluriyo for Advanced ER-Positive Breast Cancer

Medicines and Healthcare products Regulatory Agency Approves Inluriyo for Advanced ER-Positive Breast Cancer

The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.

Metastatic Breast Cancer | 26/02/2026 | By News Bureau 107

Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer

Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer

Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />

Metastatic Breast Cancer | 08/10/2025 | By Dineshwori 505

Roche Reports Positive Results from Phase III evERA Breast Cancer Study

Roche Reports Positive Results from Phase III evERA Breast Cancer Study

Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

Metastatic Breast Cancer | 24/09/2025 | By Dineshwori 147

Novartis Reports Double-Digit Sales Growth In Q2, Raises Full-Year Guidance

Novartis Reports Double-Digit Sales Growth In Q2, Raises Full-Year Guidance

Novartis has reported a robust financial performance for the second quarter of 2025, with net sales reaching USD 14.1 billion, up 12 percent year-on-year.

Metastatic Breast Cancer | 17/07/2025 | By Dineshwori 1161

Zydus Gets Approval from COFEPRIS to Market Mamitra

Zydus Gets Approval from COFEPRIS to Market Mamitra

Zydus Lifesciences has announced that COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval for Mamitra, a Trastuzumab biosimilar.

Metastatic Breast Cancer | 31/07/2024 | By Aishwarya 732


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members